Sarepta gene therapy Fast Track’d for Duchenne muscular dystrophy

July 24, 2020

The FDA designates Sarepta Therapeutics’ (NASDAQ:SRPT) gene transfer therapy SRP-9001 for Fast Track review for the treatment of Duchenne muscular dystrophy (DMD), an Orphan Drug and Rare Pediatric Disease-tagged indication.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

https://seekingalpha.com/news/3594777-sarepta-gene-therapy-fast-trackd-for-duchenne-muscular-dystrophy